Advertisement
IBB vs IDNA
Which ETF would AI Choose? iShares Biotechnology ETF (IBB) vs. iShares Genomics Immunology and Healthcare ETF (IDNA)
Key Takeaways
- iShares Biotechnology ETF (IBB) offers broad exposure to the U.S. biotechnology sector through a market-capitalization-weighted index with approximately 243 holdings, providing greater diversification compared to narrower thematic funds.
- iShares Genomics Immunology and Healthcare ETF (IDNA) targets global companies benefiting from genomics, immunology, and bioengineering innovation, resulting in a more concentrated portfolio of about 50 holdings and a slightly higher expense ratio.
- Both ETFs operate as passive, rules-based vehicles within the healthcare sector, but IBB emphasizes established biotechnology firms while IDNA incorporates a thematic focus that includes international exposure.
- IBB maintains a lower expense ratio of 0.44% versus 0.47% for IDNA, which can contribute to improved long-term cost efficiency for investors seeking broad sector access.
- IDNA exhibits higher concentration risk and potentially elevated volatility due to its smaller number of holdings and emphasis on innovative sub-themes, whereas IBB benefits from wider liquidity and a longer operational history since 2001.
- In the current market environment, both ETFs respond to shared catalysts such as regulatory developments in drug approvals and advancements in life sciences, though their differing exposure profiles lead to distinct risk-return dynamics.
Introduction
Investors comparing biotechnology and genomics-focused exchange-traded funds (ETFs) often evaluate iShares Biotechnology ETF (IBB) and iShares Genomics Immunology and Healthcare ETF (IDNA) for targeted healthcare exposure. These two funds do not compete directly but instead provide alternative strategies within the same broad sector: IBB delivers diversified access to U.S. biotechnology companies, while IDNA pursues a thematic approach centered on genomics and immunology innovation across global markets. This comparison highlights structural differences that can help investors align selections with specific objectives such as diversification needs or thematic conviction.
iShares Biotechnology ETF (IBB) Overview
The iShares Biotechnology ETF (IBB) seeks to track the NYSE Biotechnology Index, which comprises U.S.-listed equities in the biotechnology sector. Launched in 2001, it employs a passive, market-capitalization-weighted methodology and holds approximately 243 securities. Top holdings typically include Gilead Sciences (GILD), Amgen (AMGEN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Moderna (MRNA), with the top 10 positions accounting for roughly half of assets. Sector allocation centers on biotechnology (around 88%) and life sciences tools and services (around 9%). The fund charges an expense ratio of 0.44% and maintains strong liquidity through high trading volume on the NASDAQ exchange. Its non-diversified structure allows concentrated exposure to the sector while benefiting from broad representation across market capitalizations.
iShares Genomics Immunology and Healthcare ETF (IDNA) Overview
The iShares Genomics Immunology and Healthcare ETF (IDNA) tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index, focusing on developed and emerging market companies positioned to benefit from long-term growth in genomics, immunology, and bioengineering. Introduced in 2019, it uses a passive, rules-based approach with approximately 50 holdings. Prominent positions often feature Moderna (MRNA), Twist Bioscience (TWST), Iovance Biotherapeutics (IOVA), Genmab (GMAB), and Revolution Medicines (RVMD). The portfolio allocates nearly 100% to health care and incorporates meaningful international exposure. With an expense ratio of 0.47%, the ETF offers a more concentrated thematic strategy suited to investors seeking innovation-driven opportunities, though its smaller size and narrower focus result in lower average daily volume relative to broader peers.
Industry and Thematic Backdrop
The biotechnology and genomics sectors operate within a dynamic healthcare landscape influenced by ongoing innovation in therapeutic development, regulatory pathways for novel treatments, and capital allocation toward precision medicine. Macroeconomic factors such as interest rate expectations and broader equity market sentiment affect funding availability for research and development. Both ETFs face sector-specific risks including clinical trial outcomes, intellectual property challenges, and policy shifts related to drug pricing. Recent market cycles have highlighted resilience in established biotechnology platforms alongside heightened interest in genomics applications, creating an environment where diversified and thematic vehicles can serve complementary roles depending on investor time horizons and risk tolerance.
Performance and Positioning Comparison
Over recent market cycles, iShares Biotechnology ETF (IBB) has demonstrated more stable relative positioning due to its broader holdings base and emphasis on larger-capitalization biotechnology leaders, which can moderate volatility during sector rotations. In contrast, iShares Genomics Immunology and Healthcare ETF (IDNA) has shown greater sensitivity to momentum in genomics and immunology themes, potentially amplifying returns during periods of strong innovation-driven sentiment while exhibiting higher drawdowns in risk-off environments. Differences in geographic scope and concentration levels contribute to distinct performance drivers: IBB benefits from U.S.-centric stability and earnings consistency among top holdings, whereas IDNA captures global opportunities that may respond differently to international regulatory or macroeconomic developments. Investors assessing relative positioning often weigh these characteristics against personal diversification preferences and exposure goals.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore opportunities with the AI Screener.
Tickeron AI Verdict
Based on observable factors including lower expense ratio, substantially greater number of holdings for enhanced diversification, larger asset base supporting liquidity, and established track record, Tickeron’s AI would currently assign a higher probabilistic preference to iShares Biotechnology ETF (IBB) for investors seeking broad, cost-efficient biotechnology exposure. iShares Genomics Immunology and Healthcare ETF (IDNA) may appeal in scenarios prioritizing concentrated thematic exposure to genomics and immunology advancements, though its narrower profile introduces elevated concentration considerations. This assessment reflects structural attributes rather than short-term market fluctuations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IBB is a Hold and IDNA is a Hold.
IBB's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for IBB turned positive on October 20, 2026. Looking at past instances where IBB's MACD turned positive, the stock continued to rise in 44 of 49 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on IBB as a result. In 80 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
IBB moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBB advanced for three days, in 273 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 10-day moving average for IBB crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
IBB broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IBB entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
IDNA in +4.25% Uptrend, advancing for three consecutive days on October 21, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where IDNA advanced for three days, in 238 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on IDNA as a result. In 75 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 167 of 197 cases where IDNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Bearish Trend Analysis
The 10-day RSI Indicator for IDNA moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 18 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 82%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Moving Average Convergence Divergence Histogram (MACD) for IDNA turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 42 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
IDNA broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
| IBB | IDNA | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 82% |
| Stochastic ODDS (%) | 2 days ago 87% | 2 days ago 80% |
| Momentum ODDS (%) | 2 days ago 88% | 2 days ago 84% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 81% |
| TrendWeek ODDS (%) | 2 days ago 84% | 2 days ago 88% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 89% |
| Advances ODDS (%) | 3 days ago 85% | 3 days ago 85% |
| Declines ODDS (%) | 11 days ago 83% | 11 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 86% | 2 days ago 86% |
| Aroon ODDS (%) | 2 days ago 84% | 2 days ago 85% |
Advertisement
IBB and
Correlation & Price change
A.I.dvisor indicates that over the last year, IBB has been closely correlated with VRTX. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if IBB jumps, then VRTX could also see price increases.
| Ticker / NAME | Correlation To IBB | 1D Price Change % | ||
|---|---|---|---|---|
| IBB | 100% | -0.95% | ||
| VRTX - IBB | 68% Closely correlated | +2.03% | ||
| CRSP - IBB | 63% Loosely correlated | -1.01% | ||
| AMGN - IBB | 61% Loosely correlated | +2.04% | ||
| EDIT - IBB | 60% Loosely correlated | -0.80% | ||
| BEAM - IBB | 59% Loosely correlated | -1.13% | ||
More | ||||
IDNA and
Correlation & Price change
A.I.dvisor indicates that over the last year, IDNA has been loosely correlated with FATE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if IDNA jumps, then FATE could also see price increases.
| Ticker / NAME | Correlation To IDNA | 1D Price Change % | ||
|---|---|---|---|---|
| IDNA | 100% | -3.89% | ||
| FATE - IDNA | 57% Loosely correlated | +0.97% | ||
| DNA - IDNA | 51% Loosely correlated | -3.00% | ||
| RCUS - IDNA | 51% Loosely correlated | +1.36% | ||
| SANA - IDNA | 51% Loosely correlated | +0.85% | ||
| BNGO - IDNA | 51% Loosely correlated | -5.60% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| VTN | 9.81 | 0.11 | +1.13% |
| Invesco Trust for Investment Grade New York Municipals | |||
| UTF | 26.08 | 0.20 | +0.77% |
| Cohen & Steers Infrastructure Fund | |||
| BAMY | 26.55 | 0.03 | +0.12% |
| Brookstone Yield ETF (BAMY) | |||
| DJTU | 5.75 | -0.06 | -1.03% |
| T-REX 2X Long DJT Daily Target ETF (DJTU) | |||
| TTEQ | 39.57 | -2.24 | -5.36% |
| T. Rowe Price Technology ETF (TTEQ) | |||